UPDATE :NEWS [ $CSDX : Appoints Shah Teelani & Associates, a Dubai-Based PCAOB Auditor, to Consolidate All 2025 Financial Statements for CSDX, CS Interpharm GT LLC and CS Diagnostics Pharma GmbH
CHEYENNE, Wyo., Feb. 11, 2026 (GLOBE NEWSWIRE) -- CS Diagnostics Corp. (OTCQB: CSDX) (“CS Group” or the “Company”), a medical technology and hygiene solutions company, today announced the appointment of Shah Teelani & Associates, a Dubai-based Public Company Accounting Oversight Board (PCAOB) registered audit firm, to consolidate and audit the Group 2025 financial statements.
Under the engagement, Shah Teelani & Associates will oversee the consolidation and audit of financial statements for:
CS Diagnostics Corp. (OTCQB: CSDX)
CS Interpharm GT LLC
CS Diagnostics Pharma GmbH
The engagement reflects the Group’s continued commitment to strengthening financial governance, regulatory compliance, and transparency as it advances its international expansion strategy across the United States, GCC region, and Europe.
Management stated that appointing a PCAOB-registered audit firm is a significant step in aligning the Group’s financial reporting structure with U.S. public company standards while integrating its growing international companies under a unified reporting framework. The consolidated audit will support enhanced financial clarity, streamlined reporting processes, and strengthened investor confidence.
The 2025 consolidated financial review will encompass operations related to the MEDUSA hygiene and disinfectant platform, international distribution expansion.
“Engaging Shah Teelani & Associates as our PCAOB-registered auditor represents an important milestone in CS Group’s evolution as a publicly traded company,” said Mohammad Essayed, Group Chief Financial Officer. “As we scale operations across multiple regions, it is essential that our financial reporting structure reflects institutional-grade standards, transparency, and regulatory compliance. This appointment strengthens our governance foundation and supports our long-term growth strategy.”
The Group continues to focus on expanding its manufacturing partnerships, regulatory positioning, international distribution agreements, and capital markets readiness as part of its broader global growth roadmap.
About CS Diagnostics Corp
CS Diagnostics Corp. (OTCQB: CSDX) is a medical technology company advancing a dual-focus platform across infection control and oncology, targeting high-priority global healthcare markets. The Company’s portfolio includes MEDUSA, a smart disinfectant and hygiene solutions platform expanding into wet wipes and liquid formulations for institutional and consumer use, and CS Protect-Hydrogel, a tissue spacer designed to protect healthy organs during prostate cancer radiotherapy. CSDX is progressing through key commercialization milestones, including strategic manufacturing partnerships, multi-region launches across the GCC and Europe, diversified B2B and B2C distribution channels, global logistics agreements, and a growing intellectual property and regulatory roadmap.
CS Diagnostics Corp. (OTCQB:CSDX)
Transforming healthcare through innovation and shaping the future of medical technology
Discover the future of healthcare at CS Diagnostics Corp. With our focus on improving therapy outcomes and reducing side effects, we are revolutionizing patient care on a global scale.
Who We Are
CS Diagnostics Corp. a renowned member of the CS Group, is a medical sector leader committed to advancing patient care through innovative solutions. With decades of experience in designing, manufacturing, and selling wellness and medical products, we have established ourselves as a reliable partner in global healthcare.
What We Do
CS Diagnostics Corp. serves a varied international market and specializes in traversing complicated regulatory landscapes to gain product approval and distribution. Our global presence is enhanced by strategic collaborations with healthcare sectors globally, ensuring that our comprehensive services and solutions are available in multiple countries. With a focus on quality and a strong range of solutions, CS Diagnostics Corp. is well-positioned to change the future of healthcare by delivering on our promise of greater health through better technology.
MEDUSA
Introducing the CS-Protect Hydrogel
Experience the future of radiation therapy with our revolutionary hydrogel spacer. Designed to safeguard healthy tissue during prostate cancer treatment, it sets a new standard in precision medicine. As the pinnacle of innovation in prostate cancer care, it maximizes treatment accuracy while minimizing collateral damage, ensuring patients receive cutting-edge care throughout their therapeutic journey.
No comments